Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.
复制标题
乳腺癌存活率由 ER/PR/HER2 亚型和根据肿瘤分级和免疫组织化学生物标志物的替代分类定义。
DOI：
10.1155/2014/469251
复制
发表时间：
2014
影响因子：
1.8
通讯作者：
Caggiano V
中科院分区：
文献类型：
--
作者：
Parise CA;Caggiano V
介绍。 ER、PR 和 HER2 通常可在乳腺癌样本中找到。本研究的目的是将八种 ER/PR/HER2 亚型的乳腺癌特异性生存率与基于 ER/PR/HER2 亚型和肿瘤分级的分子亚型的免疫组织化学替代物的生存率进行对比。方法。我们从加州癌症登记处发现了 123,780 例 1-3 期原发性女性浸润性乳腺癌病例。替代分类是使用 ER/PR/HER2 和肿瘤分级得出的。 Kaplan-Meier 生存分析和 Cox 比例风险模型用于评估每个阶段内 ER/PR/HER2 亚型和替代分类的生存和死亡风险差异。结果。对于所有疾病阶段，Luminal B/HER2− 替代分类的死亡风险均高于 Luminal B/HER2+。第 3 阶段 ER+/PR+/HER2− 和 ER+/PR+/HER2+ 之间的死亡风险没有差异。除了第 3 阶段的一个例外，与 ER 阳性亚型相比，ER 阴性亚型的死亡风险均增加。结论。使用 ER/PR/HER2 进行的生存评估说明了 HER2+ 亚型的异质性。替代分类明确区分了生存率和调整死亡率，但低估了构成分类的亚型内的广泛变异性。
Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The purpose of this study is to contrast breast cancer-specific survival for the eight ER/PR/HER2 subtypes with survival of an immunohistochemical surrogate for the molecular subtype based on the ER/PR/HER2 subtypes and tumor grade. Methods. We identified 123,780 cases of stages 1–3 primary female invasive breast cancer from California Cancer Registry. The surrogate classification was derived using ER/PR/HER2 and tumor grade. Kaplan-Meier survival analysis and Cox proportional hazards modeling were used to assess differences in survival and risk of mortality for the ER/PR/HER2 subtypes and surrogate classification within each stage. Results. The luminal B/HER2− surrogate classification had a higher risk of mortality than the luminal B/HER2+ for all stages of disease. There was no difference in risk of mortality between the ER+/PR+/HER2− and ER+/PR+/HER2+ in stage 3. With one exception in stage 3, the ER-negative subtypes all had an increased risk of mortality when compared with the ER-positive subtypes. Conclusions. Assessment of survival using ER/PR/HER2 illustrates the heterogeneity of HER2+ subtypes. The surrogate classification provides clear separation in survival and adjusted mortality but underestimates the wide variability within the subtypes that make up the classification.
登录
查看更多内容
影响因子：
6.2
作者：
Kurian, Allison W.;Mitani, Aya;Desai, Manisha;Yu, Peter P.;Seto, Tina;Weber, Susan C.;Olson, Cliff;Kenkare, Pragati;Gomez, Scarlett L.;de Bruin, Monique A.;Horst, Kathleen;Belkora, Jeffrey;May, Suepattra G.;Frosch, Dominick L.;Blayney, Douglas W.;Luft, Harold S.;Das, Amar K.
通讯作者：
Das, Amar K.
影响因子：
50.5
作者：
Brouckaert, O.;Schoneveld, A.;Neven, P.
通讯作者：
Neven, P.
DOI：
10.1186/bcr3462
发表时间：
2013
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Hefti MM;Hu R;Knoblauch NW;Collins LC;Haibe-Kains B;Tamimi RM;Beck AH
通讯作者：
Beck AH
影响因子：
3.8
作者：
Lips, E. H.;Mulder, L.;de Ronde, J. J.;Mandjes, I. A. M.;Koolen, B. B.;Wessels, L. F. A.;Rodenhuis, S.;Wesseling, J.
通讯作者：
Wesseling, J.
影响因子：
6.2
作者：
Ou, S. -H. Ignatius;Zell, Jason A.;Anton-Culver, Hoda
通讯作者：
Anton-Culver, Hoda